10 April 2017

Redx Pharma presents data in oncology and fibrosis at two key scientific congresses


Redx Pharma, the research and development company focused on cancer, immunology and infection, recently presented scientific posters in oncology and fibrosis at the American Association for Cancer Research (AACR) Annual Meeting on April 1-5, 2017, in Washington D.C., USA and the Keystone Symposia (Keystone) focused on Injury, Inflammation and Fibrosis, on March 26-30, 2017, in Snowbird, Utah, USA, respectively.

“The posters recently presented at key scientific congresses demonstrate that our discovery engine continues to produce the next potential therapies for high value unmet needs in oncology and immunology. We have previously seen that Porcupine inhibitors have shown potential applications in oncology, however we are pleased that we are now able to present validated preclinical data demonstrating that they could also be efficacious against fibrosis. As a result of this we now believe there are many development opportunities in an area that has seen little meaningful therapeutic progress for patients.”

Dr Neil Murray

Chief Executive Officer of Redx Pharma



Title: Porcupine inhibitors demonstrate suitability for use as novel anti-fibrotic therapeutics

Author: Peter Bunyard

Summary: REDX06109 demonstrated a robust anti-fibrotic response when dosed therapeutically in an animal model of kidney fibrosis at levels that are expected to be well tolerated. Preliminary data also showed that Wnt ligand is a potent stimulator of human lung fibroblast proliferation and is likely to synergise with other pro-fibrotic mediators to induce an aggressive fibrotic response to tissue injury.




Title: Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS tumors

Author: Helen Mason

Summary: REDX05358 is a highly potent and selective inhibitor targeting all RAF isoforms, which demonstrates anti-proliferative activity across a range of mutant cancer cell lines. Unlike the first generation RAF inhibitor, vemurafenib, which only shows transient inhibitory effects in mutant RAF colorectal cancer, REDX05358 sustains inhibition of this pathway and overcomes the resistance seen with vemurafenib both in vitro and in vivo. REDX05358 presents a potential therapeutic opportunity for the treatment of mutant cancers.



Title: Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO-1) selective inhibitors

Author: Caroline Phillips

Summary: A novel chemical series was identified via an in silico virtual screening method with potent cellular activity against the IDO-1 enzyme, both in cancer cell lines and human dendritic cells. Experiments in dendritic cells have revealed differences between the Redx compound series and reference compounds in their inhibitory responses to varying stimulating conditions.



For further information, please contact: 

Redx Pharma Plc
Neil Murray, Chief Executive Officer
T: +44 1625 469 900
Karl Hård, Head of Investor Relations &

Corporate Communications
T: +44 7491 651 406

Cantor Fitzgerald Europe (Nomad & Broker)
T: +44 20 7894 7000
Phil Davies/ Michael Reynolds

WG Partners LLP (Joint Broker)
T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson

Consilium Strategic Communications
Amber Fennell/ Matthew Neal/ Melissa Gardiner
T: +44 20 3709 5700

About Redx Pharma Plc

Company website: www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

Back to previous page